Most of the breakthrough science in pharma continues to come from emerging biotechs, while the size, scale, expertise and connections of big pharma are still essential. How strategies are evolving in this situation was the subject of ‘Early-Stage Pharma Partnering – Building a Strategy For Success’, a big pharma panel at the LSX World Congress in London on 4 May.
What Do They Want? Securing The Big Pharma Deal
Partnering has changed in many ways in the last 18 months. Financial markets have all but closed to start-ups and investors are consolidating asset bases in the expectation of relatively high inflation continuing for the next few years.
